87 completed. 87 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 87 | Completed 87 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden Lebrikizumab - Atopic Dermatitis | Phase 4 | Completed | Eli Lilly and Company | 233 | 2025-06-16 | 2026-10-15 |
| A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis Upadacitinib - Atopic Dermatitis | Phase 4 | Completed | AbbVie | 461 | 2023-05-29 | 2025-07-29 |
| Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis Triamcinolone Acetonide (Aristocort® C), Vehicle - Atopic Dermatitis | Phase 4 | Completed | Innovaderm Research Inc. | 20 | 2023-05-09 | 2025-03-26 |
| Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis Dupilumab step-down - Atopic Dermatitis, Eczema, Atopic | Phase 4 | Completed | Nantes University Hospital | 256 | 2023-03-08 | 2026-09-24 |
| Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China Dupilumab - Atopic Dermatitis | Phase 4 | Completed | Sanofi | 34 | 2023-02-22 | 2025-02-10 |
| Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial dupilumab, Topical emollient (moisturizer) - Moderate-to-Severe Atopic Dermatitis, Atopic Eczema | Phase 4 | Completed | Regeneron Pharmaceuticals | 124 | 2023-01-11 | 2026-05-27 |
| Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab Abrocitinib - Atopic Dermatitis | Phase 4 | Completed | Innovaderm Research Inc. | 24 | 2022-11-25 | 2025-03-28 |
| Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China Dupilumab - Atopic Dermatitis, Dermatitis Atopic | Phase 4 | Completed | Sanofi | 44 | 2022-11-25 | 2025-09-15 |
| Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide - Atopic Dermatitis | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 433 | 2022-11-21 | 2026-06-04 |
| Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis Dupilumab (SAR231893) - Dermatitis Atopic | Phase 4 | Completed | Sanofi | 54 | 2021-04-22 | 2025-09-16 |
| Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis Dupilumab SAR231893 - Dermatitis Atopic | Phase 4 | Completed | Sanofi | 41 | 2021-02-19 | 2025-09-15 |
| Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates Mometasone Furoate - Atopic Dermatitis | Phase 4 | Completed | Libbs Farmacêutica LTDA | 32 | 2020-11-23 | 2023-10-11 |
| The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment Dupilumab Prefilled Syringe - Atopic Dermatitis, Eczema | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2020-09-01 | 2023-02-08 |
| Dupilumab Skin Barrier Function Study in Atopic Dermatitis Dupilumab SAR231893 - Atopic Dermatitis | Phase 4 | Completed | Sanofi | 52 | 2020-07-16 | 2025-09-18 |
| Steroid-reducing Effects of Crisaborole Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment - Atopic Dermatitis, Eczema | Phase 4 | Completed | Johns Hopkins University | 24 | 2019-12-17 | 2024-07-19 |
| Response of Children With Atopic Dermatitis (Eczema) to Eucrisa Crisaborole - Atopic Dermatitis, Eczema | Phase 4 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 30 | 2019-10-03 | 2022-07-19 |
| The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Betnovate, betamethasone dipropionate ointment 0.1% and placebo, Protopic, tacrolimus ointment 0.1% - Atopic Dermatitis, Atopic Eczema | Phase 4 | Completed | Jacob Thyssen | 36 | 2019-08-22 | 2021-04-28 |
| SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" Dupilumab, Placebo - Atopic Dermatitis | Phase 4 | Completed | Sanofi | 188 | 2019-08-22 | 2025-09-17 |
| Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis Crisaborole 2%, Placebo ointment - Dermatitis, Atopic | Phase 4 | Completed | Innovaderm Research Inc. | 31 | 2019-05-21 | 2021-08-24 |
| The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Completed | University of California, San Francisco | 34 | 2018-11-01 | 2024-01-09 |
Showing 20 of 87. Sign in to see all of them.
Eczema (18) · Dermatitis (4) · Pruritus (4) · Psoriasis (4) · Asthma (2) · Facies (2) · Lymphoma, Follicular (2) · Bronchiolitis Obliterans Syndrome (1) · Coinfection (1) · Conjunctivitis, Allergic (1) · Folliculitis (1) · Impetigo (1) · Infections (1) · Inflammation (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (87) · Genetic Diseases, Inborn (87) · Hypersensitivity (87) · Hypersensitivity, Immediate (87) · Immune System Diseases (87) · Skin Diseases (87) · Skin Diseases, Eczematous (87) · Skin Diseases, Genetic (87) · Skin and Connective Tissue Diseases (87) · Dermatitis (83) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (4) · Skin Diseases, Papulosquamous (4) · Skin Manifestations (4) · Bronchial Diseases (3)
pimecrolimus (18) · dupilumab (11) · Tacrolimus (8) · crisaborole (4) · Omalizumab (3) · montelukast (3) · Adrenal Cortex Hormones (2) · Fluocinonide (2) · Fluticasone (2) · Petrolatum (2) · Triamcinolone Acetonide (2) · methylprednisolone aceponate (2) · retapamulin (2) · Alefacept (1) · Baths (1)
Novartis (10) · Astellas Pharma Inc (6) · Sanofi (6) · Derm Research, PLLC (3) · Innovaderm Research Inc. (3) · Wake Forest University (3) · Wake Forest University Health Sciences (3) · Casa Espirita Terra de Ismael (2) · Ceragenix Pharmaceuticals (2) · Fougera Pharmaceuticals Inc. (2) · Janssen-Cilag Ltd.,Thailand (2) · Novartis Pharmaceuticals (2) · Technische Universität Dresden (2) · University of California, San Francisco (2) · 1st Allergy & Clinical Research Center (1)
United States (45) · Canada (8) · Germany (8) · United Kingdom (6) · Brazil (5) · Australia (4) · China (4) · France (4) · Switzerland (4) · Finland (3) · Spain (3) · Austria (2) · Belgium (2) · Italy (2) · Vietnam (2)
Robert Bissonnette, MD (3) · Leon H. Kircik, M.D. (2) · Adelaide A Hebert, M.D. (1) · Adelaide A Hebert, MD (1) · Adnan Nasir, MD, PhD (1) · Alan Fleischer Jr., M.D. (1)
PMID 19127072, PMID 19403473, PMID 19863501, PMID 21099191, PMID 21121981, PMID 21533301, PMID 24435467, PMID 28330497, PMID 28491950, PMID 31764962, PMID 32212104, PMID 36824052, PMID 37181420, PMID 41350756, PMID 41611123, PMID 42027418, PMID 42126851
2004 (1), 2018 (1)